JPMorgan analyst Brian Cheng raised the firm’s price target on Zymeworks (ZYME) to $23 from $20 and keeps an Overweight rating on the shares. The firm also placed the shares on “Positive Catalyst Watch.” Zymeworks next Thursday will be presenting initial data from the FR-targeting ADC Phase 1 trial, the analyst tells investors in a research note. JPMorgan believes there is “underappreciated upside potentia”l from next week’s ZW191 catalyst. The data could provide further upside that is not yet reflected in the stock today, contends the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks’ Promising Pipeline and Financial Projections Lead to Buy Rating
- Zymeworks upgraded to Buy from Neutral at H.C. Wainwright
- Zymeworks Presents Promising Phase 1 Data for ZW191 at International Conference
- Align downgraded, NetEase upgraded: Wall Street’s top analyst calls
- Zymeworks initiated with a Buy at B. Riley